Navigation Links
InteKrin Therapeutics Announces $20 Million Series C Financing
Date:8/4/2008

LOS ALTOS, Calif., Aug. 4 /PRNewswire/ -- InteKrin Therapeutics, Inc., a clinical stage biopharmaceutical company focused on the development of products for diabetes, metabolism and obesity today announced it has completed the first close of a Series C venture financing for $18.25 million. The financing was led by Skyline Ventures of Palo Alto, CA and Managing Director David Lowe Ph.D. of Skyline will join InteKrin's Board of Directors. Existing major investors Sofinnova Ventures and OrbiMed Advisors also significantly participated, as did other earlier investors. The Company anticipates a second close of the Series C bringing the total for the round to $20 million to support the continued development of INT131, a non-TZD selective modulator of PPAR gamma (SPPARM) for treatment of Type II diabetes (T2DM).

"InteKrin is very pleased to have Skyline, a premier health care venture firm, lead its Series C financing," remarked InteKrin's President and CEO Denny Lanfear. "This investment and the ongoing support of our existing investors including Sofinnova and OrbiMed will allow us to fully prepare INT131 for the initiation of the Phase 3 studies in 1H10 and maintain our rapid development pace."

"The nonclinical safety multiples seen with INT131 together with the strong efficacy seen in the Phase 2a study present a unique profile," commented Skyline Ventures' David Lowe Ph.D. "The biology of INT131 and its demonstrated ability to selectively modulate PPAR gamma promises to deliver to patients glucose lowering efficacy without the safety compromises of currently available insulin sensitizers."

INT131 was designed specifically to antagonize characteristic TZD adverse effects while retaining powerful PPAR gamma anti-diabetic efficacy, and represents a new product and chemical class. INT131 is well positioned to fulfill the unmet medical need for a safe treatment of insulin resistance, the key etiological feature in the onset and subsequent progress
'/>"/>

SOURCE InteKrin Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... Orlando, Florida (PRWEB) January 22, 2015 ... up today at the 2015 PGA Merchandise Show to ... lady and incredible female amateur golfer, Arlene McKitrick. The ... career female amateur golf tournament win. She won her ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
(Date:1/22/2015)... January 23, 2015 Recently, Weddingshe.com has added ... and has announced its highest annual revenues in the past ... its popular glamorous wedding dresses. , According to the sales ... wedding dress promotions for them in 2015. This point can ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... job of communicating critical elements of medication use when they ... has found//. ,The study, slated for publication in the ... that in too many instances, physicians did not address such ... effects or even the names of drugs they were prescribing ...
... of Technology are proposing a revolutionary approach to ... (re-clogging of coronary arteries). ,More than 1.2 ... in 2003, according to the American Heart Association. ... during which a tiny deflated balloon is inserted ...
... Washington: A finding by the advocacy group, Families USA, suggests ... have at least one parent employed full-time//. And in 25% ... members. ,The group's executive director, Ron Pollack said ... work, who are very different from themselves. These are people ...
... with Simcere Pharmaceutical Group of Nanjing, China for it ... flu drug Relenza in poor countries//. ,The ... Indonesia, Thailand, Vietnam and all least-developed countries, under the ... everything we can to prepare for a global influenza ...
... California, San Diego and Yale University have discovered that ... sprayed// on crops by organic farmers to reduce insect ... laboratory animals. ,Their discovery, detailed in this week’s ... Academy of Sciences, could pave the way for the ...
... therapy with statin medications reduces death and cardiovascular ... or other acute heart events//, according to an ... levels, have clearly been shown to benefit patients ... the article. However, it is less clear whether ...
Cached Medicine News:Health News:Physician Communication Spotty When Prescribing Medications 2Health News:Novel Technique Would Prevent Re-Clogged Arteries 2Health News:Bacterial Protein Shows Promise in Treating Intestinal Parasites 2Health News:Bacterial Protein Shows Promise in Treating Intestinal Parasites 3Health News:Early Statin Therapy for Patients Reduces Death, Cardiovascular Events 2
(Date:1/23/2015)... Jan. 23, 2015  Today the U.S. Food and Drug ... the prevention of serogroup B meningococcal disease ... vaccine Trumenba®, which received FDA approval in October, represent ... disease. "I have heard over and ...
(Date:1/23/2015)... , Jan. 23, 2015  The Partnership to Fight Chronic Disease ... health care leaders and a new study analyzing the impact ... PFCD is a nationwide coalition working to educate policy makers and ... at the Capitol was focused on how the Iowa ...
(Date:1/23/2015)... 23, 2015 More than a third of reproductive-aged women ... with private insurance, filled a prescription for an opioid pain ... this week,s Morbidity and Mortality Weekly Report (MMWR). ... treat moderate to severe pain.  They are also found in ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... hold its annual meeting of stockholders on Wednesday, June 9, 2010 at 9:00a.m. Pacific Time for all stockholders of record on ... ... , , ... ...
... the Barclays 2010 Global Healthcare Conference on March 23, 2010 at 1:30 p.m. eastern at the Loews Hotel in Miami, Florida . , ... , ... ... ...
Cached Medicine Technology:PDL BioPharma To Hold Annual Meeting of Stockholders on June 9, 2010 2Express Scripts to Present at Barclays 2010 Global Healthcare Conference 2
... Cytometry Concentrate is for use as a ... cytometry. Each 70ml bottle of Cytometry Concentrate ... distilled water. Compared to Cubitainers, Streck Cytometry ... and saves money without compromising performance. Streck ...
... CD34 is a stabilized preparation ... can be used as a ... CD34 positive cells. It is ... ProCOUNT gating strategies. CD-Chex CD34 ...
... A lytic reagent manufactured ... determination of hemoglobin and ... Agent IIIA is manufactured ... the Abbott CELL-DYN® 1700. ...
Streck-Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3000. The shelf life is two years from the date of manufacture....
Medicine Products: